Document text
Principal Investigator: Troy Michael Bankhead
Organization: WASHINGTON STATE UNIVERSITY
Fiscal Year: 2024
Award: $382,500
Funding agency: National Institute of Allergy and Infectious Diseases
Summary
The ability of Borrelia burgdorferi to cause Lyme disease is highly dependent on its capacity to
establish a successful infection upon entering the mammalian host. Moreover, survival of the pathogen in
nature is completely dependent on its enzootic life cycle involving both a tick and reservoir host. The transition
between these two very different host types requires the ability to rapidly adapt through changes in gene
expression. Recent studies in our lab have provided evidence of the importance of lp17-resident genes for
plasmid copy number control and resultant gene dosage effects that may have significant roles in host
adaptation by B. burgdorferi. Despite this advance, there remains a fundamental gap in our understanding of
the functional and mechanistic aspects of currently identified lp17-encoded factors. The overall objective of this
application is to establish the functional outcome of lp17 copy number on gene dosage effects that correlate to
the ability of the pathogen to adapt to the host environment. Additionally, we aim to determine that mechanism
of action by the regulatory sRNA of lp17, SR0726, during host infection. Based on published and preliminary
data, the central hypothesis is that bbd21-22 are important for proper copy number control of multiple B.
burgdorferi plasmids that result in dosage effects of lp17-resident genetic factors important for host adaptation
and tissue colonization. The rationale for the proposed research is that the expected outcomes will significantly
advance our knowledge of the role that lp17 genes play in host adaptation by B. burgdorferi, and could
ultimately lead to the identification of potential targets for the development of a vaccine and/or therapeutics
against human infection. Thus, the proposed research is relevant to that part of NIH’s mission that pertains to
developing fundamental knowledge that will potentially help to reduce the burdens of human illness and
disability. Guided by our preliminary data, our hypothesis will be tested by pursuing two specific aims: 1)
Establish the importance of bbd21 and bbd22 for copy number control of B. burgdorferi plasmids and gene
dosage effects, and 2) Determine the regulatory mechanism of SR0726 during host infection. Under the first
aim, the effects of bbd21 and/or bbd22 deletion on copy number control of plasmids other than lp17 will be
examined, the ability of BBD21 and BBD22 to interact assessed, and the capacity of BBD21 and/or BBD22 to
specifically bind DNA regions of multiple plasmids established. In the second aim, the approaches used will
include RIL-seq analysis of SR0726 binding to target mRNA, mutational analysis of predicted complementarity
binding regions of SR0726, and delineation of the upstream region necessary for regulated expression of
SR0726. The proposed work is innovative because it involves the first mutational analysis of these lp17-
resident genes in an infectious background strain to assess their mechanistic importance for both plasmid
maintenance and gene regulation. When applied, the knowledge gained from the proposed studies have the
potential to elucidate new drug targets to treat and prevent Lyme disease.
Terms: <Affect><Animals><Area><B burgdorferi><B. burgdorferi><Band Shift Mobility Assay><Bandshift Mobility Assay><Binding><Body Tissues><Borrelia burgdorferi><Borrelia burgdorferi sensu stricto><Borreliella burgdorferi><ChIP Sequencing><ChIP-seq><ChIPseq><Chromosomes><Chronic><Clinical><DNA><DNA Binding><DNA Binding Interaction><DNA bound><Data><Deoxyribonucleic Acid><Dialysis><Dialysis procedure><Down-Regulation><Electrophoretic Mobility Shift Assay><Environment><Gene Action Regulation><Gene Copy Number><Gene Dosage><Gene Expression><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene Transcription><Generations><Genes><Genetic><Genetic Transcription><Genomic Segment><Goals><Health><Heart><Human><Impairment><In Vitro><Infection><Inflammation><Intercistronic Region><Intergenic Regions><Ixodida><Joints><Knowledge><Life Cycle><Life Cycle Stages><Lyme Borreliosis><Lyme Disease><Lyme Disease Spirochete><Maintenance><Mammalia><Mammals><Membrane><Messenger RNA><Methods><Mission><Mobility Shift Assay><Modern Man><Molecular Interaction><Mutate><Mutation Analysis><NIH><National Institutes of Health><Nature><North America><OspC protein><Outcome><Outer surface protein C><Pathogenesis><Peripheral><Phenotype><Plasmids><Play><Promoter Regions><Promotor Regions><Proteins><Public Health><Publishing><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Research><Role><System><Testing><Therapeutic><Ticks><Tissues><Transcript><Transcription><United States National Institutes of Health><Vector-borne disease><Vector-borne infectious disease><Vector-transmitted disease><Vector-transmitted infectious disease><Work><chromatin immunoprecipitation-sequencing><crosslink><develop a vaccine><develop vaccines><development of a vaccine><dialysis therapy><disability><dosage><enzootic><functional outcomes><gel shift assay><genetic element><genetic promoter element><genetic promoter sequence><genome segment><genomic region><human pathogen><in vivo><innovate><innovation><innovative><life course><lyme spirochete><mRNA><membrane structure><mutant><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><ospC><pathogen><prevent><preventing><promoter sequence><qRTPCR><social role><vaccine development><vector-borne illness><vectorborne disease><vectorborne illness><vectorborne infectious disease>